ArticleBiomedical journal2021

Pristimerin exerts antitumor activity against MDA-MB-231 triple-negative breast cancer cells by reversing of epithelial-mesenchymal transition via downregulation of integrin β3.

Shiyue Liu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.